2020
DOI: 10.1208/s12249-020-01801-1
|View full text |Cite
|
Sign up to set email alerts
|

Investigation of 1,2-Dimyristoyl-sn-Glycero-3-Phosphoglycerol-Sodium (DMPG-Na) Lipid with Various Metal Cations in Nanocochleate Preformulation: Application for Andrographolide Oral Delivery in Cancer Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(7 citation statements)
references
References 62 publications
0
7
0
Order By: Relevance
“…Furthermore, ANDNCs showed minimum accumulation within the vital organs like the kidney, liver, and spleen. 65 These new delivery devices for andrographolide greatly enhance the efficiency of andrographolide in treating various diseases.…”
Section: New Delivery Systems For Andrographolidementioning
confidence: 99%
“…Furthermore, ANDNCs showed minimum accumulation within the vital organs like the kidney, liver, and spleen. 65 These new delivery devices for andrographolide greatly enhance the efficiency of andrographolide in treating various diseases.…”
Section: New Delivery Systems For Andrographolidementioning
confidence: 99%
“…Further, AGLloaded solid lipid nanoparticles inhibited head and neck cancer [43]. Andrographolide-loaded nanocochleates were assessed for their physiochemical properties to be used as an oral delivery alternative for clinical trials in cancer therapy [44]. In addition, AGL nanoparticles were also tested and established to protect against cigarette smoking-induced chronic obstructive pulmonary disease [45].…”
Section: Functional Prospective Of Andrographolide (Agl) On Human Healthmentioning
confidence: 99%
“…They may aggregate; hence addition of aggregation inhibitor is required [ 7 ]. Numerous studies have been carried out on the formulation and evaluation of nanocochleates of various anticancer agents like fisetin [ 8 ], paclitaxel [ 9 , 10 ], raloxifene [ 11 ], quercetin [ 12 ], erlotinib, and dexketoprofen [ 13 ], doxorubicin with folic acid [ 14 ], docetaxel [ 15 ], curcumin [ 16 ], hydrocamptothecin [ 17 ], cytarabine [ 18 , 19 ], and imatinib with dexketoprofen [ 20 ] and demonstrated to improve the efficacy for the treatment of various types of cancers.…”
Section: Introductionmentioning
confidence: 99%